Psyence Biomedical Ltd.(PBM)Earnings, Financials & Key Ratios
PBM•NASDAQ
$2.97
Price updated Jun 27, 2026
AboutPsyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.Show more
- Revenue$0
- EBITDA-$6M-70.3%
- Net Income-$7M-785.6%
- EPS (Diluted)0.00-100.0%
- ROE-58.62%-489.4%
PBM Price & Volume
Psyence Biomedical Ltd. (PBM) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Burn Threatens Corporate Solvency Stability
Investment Thesis • Updated 2023Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding exhaustion
"Psyence Biomedical operates as a pre-revenue clinical-stage entity, where the absence of commercial sales necessitates a heavy reliance on external capital to fund its PEX010 development pipeline. The company faces significant execution risks, as evidenced by a $24.8M net loss in 2023Q3 and a precarious liquidity position that leaves little room for operational error. Investors should monitor the firm's ability to secure non-dilutive funding, as the current trajectory of negative equity and asset erosion suggests a high probability of continued shareholder value impairment."
Verdict Logic
the company's total assets have plummeted from over $250M in 2022Q3 to a mere $1.1K by 2023Q3, indicating an unsustainable path toward clinical milestone achievement.
PBM Growth Metrics
Psyence Biomedical Ltd. (PBM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-421.02%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-827.04%
Return on Capital
10 Years-22.24%
5 Years-22.24%
3 Years-36.52%
Last Year-52.71%
Peers Comparison
Key metrics vs top competitors for Psyence Biomedical Ltd. (PBM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.97 | $39.77M | — | — | — | -58.62% | — | |
| $14.82 | $1.42B | -4.81 | — | — | -151.02% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $5.29 | $1.95B | -1.82 | 1227.6% | -19019.44% | -366.21% | — | |
| $6.09 | $303.86M | -13.66 | — | — | -81% | — | |
| $138.76 | $19.01B | 6222.42 | 2.72% | 3.46% | 2.79% | — |
Compare PBM vs Peers
Psyence Biomedical Ltd. (PBM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PBM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PBM Frequently Asked Questions
Psyence Biomedical Ltd. (PBM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is PBM profitable?
Psyence Biomedical Ltd. (PBM) reported a net loss of $25.7M for fiscal year 2025.
Dividend & Returns
What is PBM's return on equity?
Psyence Biomedical Ltd. (PBM) has a return on equity (ROE) of -58.6%. Negative ROE indicates the company is unprofitable.
What is Psyence Biomedical Ltd.'s free cash flow?
Psyence Biomedical Ltd. (PBM) had negative free cash flow of $1.1M in fiscal year 2025, likely due to heavy capital investments.